# LB PHARMACEUTICALS INC (LBRX) — capital_raise/atm_program [pending]
Source: SEC API (secapi.ai) · situation sit_ab92f2041b13e07ec8a3 · retrieved 2026-08-11T15:50:03.737Z

## Overview
LB Pharmaceuticals Inc is a pharmaceutical company developing LB-102, a drug candidate being evaluated for expansion into new indications with mechanistic rationale and validating clinical and real-world experience from amisulpride.

On July 28, 2026, LB Pharmaceuticals Inc entered into a Securities Purchase Agreement to conduct a private placement of 3,577,560 shares of common stock at $34.94 per share and pre-funded warrants to purchase 715,513 shares at $34.9399 per warrant. The gross proceeds are estimated at approximately $150.0 million, before transaction expenses. The closing is expected on or about July 30, 2026, subject to customary closing conditions. The company intends to use the net proceeds to fund pipeline expansion of LB-102 into new indications including negative symptoms of schizophrenia and Alzheimer's disease agitation/psychosis, as well as for working capital and general corporate purposes.

## Terms
- Counterparty: Institutional investors · Deal value: $150.0M · Consideration: cash · Price/share: $34.94

## Key dates
- Announced 2026-07-29 · Expected close 2026-07-30

## Timeline
- 2026-07-29 · 8-K (0001193125-26-322208): 8-K - LB PHARMACEUTICALS INC — *LB Pharmaceuticals Inc is a pharmaceutical company developing LB-102, a drug candidate being evaluated for expansion into new indications with mechanistic rationale and validating clinical and real-world experience from amisulpride.* On July 28, 2026, LB Pharmaceuticals Inc entered into a Securities Purchase Agreement to conduct a private placement of 3,577,560 shares of common stock at $34.94 per share and pre-funded warrants to purchase 715,513 shares at $34.9399 per warrant. The gross proceeds are estimated at approximately $150.0 million, before transaction expenses. The closing is expected on or about July 30, 2026, subject to customary closing conditions. The company intends to use the net proceeds to fund pipeline expansion of LB-102 into new indications including negative symptoms of schizophrenia and Alzheimer's disease agitation/psychosis, as well as for working capital and general corporate purposes.
  https://www.sec.gov/Archives/edgar/data/1691082/0001193125-26-322208.txt

## Citations
- 0001193125-26-322208 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526322208